| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Research Abstract |
This study was approved by the Ethics Committee of the Showa University (Application No. 126). Written informed consent was obtained from 798 patients (656 men and 142 women) before participation. Blood samples were collected from a peripheral vein and then genomic DNA was prepared. The Mt5178 C/A polymorphism was detected by polymerase chain reaction (PCR) and digestion with AluI restriction enzyme. The sequence of primers was: forward 5′-CTTAGCATACTCCTCAATTACCC-3′, reverse 5′-GTGAATTCTTCGATAATGGCCCA-3′. Clinical background data such ashistuory of treatment, the number of hospitalization, clinical outcome, participation of cardiac rehabilitation, family history of coronary heart diseases, diabetes, dyslipidemia, hypertension, smoking status, control of risk factors, is collecting. We divided the study subjects into 3 groups as follows; (1) Juvenile group (onset age <55 years in men and <65 years in women, n=105), (2) high age group (the present age>=80 years, n=189), and (3) the others were classified as the common group (n=504). The allelic of 5178C was observed in 436 patients (355 men and 81 women) and the allelic of 5178A in 362 patients (301 men and 61 women). The allelic frequency of 5178A was somewhat higher in the Juvenile group. In contrast to previous studies, the distribution of the allelic frequency of 5178A/C is similar to the general Japanese population, and there were no significant differences by gender and age. The association between the 5178C/A polymorphism and clinical data isinvestigating.
|
